Sign in with Google
bullish
China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi
330 Views06 Mar 2022 01:09
Junshi’s PD-1 result in April is more representative to judge FDA's attitude and globalization logic. We probably are at the tail end of mab drug innovation. The pet vaccine market is very attractive.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Toyota Industries (6201) - SURPRISE! It's a TOYODA Takeover Proposal (Good Governance May Not Win)
- Laopu Gold (6181 HK): Global Index Inclusion Likely Derailed by Full Circulation
- Toyota Industries (6201 JP): A Rumoured Privatisation with Several Unknowns
- Sigma Healthcare (SIG AU): Next Round of Passive Buying Around the Corner
- Quiddity Leaderboard STAR 50/100 Jun25: Rare Sector-Neutral ADDs Vs DELs Trade with Positive Momentum
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)
- China: EM Investors Precariously Positioned15 Mar 2022
- China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent13 Mar 2022
- Russia-Ukraine War: The Impact on China Healthcare09 Mar 2022
- China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi06 Mar 2022
- Suzhou Zelgen Biopharmaceuticals (688266.CH) - Uncertainty Leads to Inaccurate Prediction on Outlook03 Mar 2022
- China Healthcare Weekly (Feb.25)-Assisted Reproduction, Medical Device Co. Globalization, New Growth27 Feb 2022
- China Healthcare Weekly (Feb.18)-VBP Expansion, China Drug Pricing System,FDA Approval,Junshi/Legend20 Feb 2022
x